Xovoltib (Afatinib) 40mg Tablets | Taiwan Originator | GLT

Generic Information: Xovoltib (Afatinib) — Taiwan

Xovoltib is the brand name for afatinib marketed by Boehringer Ingelheim Taiwan Ltd. This listing covers the 40 mg strength in a 30-tablet pack, sourced from the Taiwan market. As the originator's own product for the region, Xovoltib delivers the same second-generation, irreversible EGFR inhibitor that is prescribed worldwide under the names Gilotrif and Giotrif, with Taiwan-specific packaging and registration.

What Is Xovoltib (Afatinib) Used For?

Xovoltib is used for the treatment of locally advanced or metastatic non-small cell lung cancer with EGFR-activating mutations, including exon 19 deletions and the L858R substitution. It is also indicated for metastatic squamous NSCLC that has progressed after platinum-based chemotherapy. It is a first-line standard for EGFR-mutant lung cancer and offers activity against uncommon EGFR mutations as well.

How Does Xovoltib (Afatinib) Work?

Xovoltib's active ingredient, afatinib, is an irreversible pan-ErbB inhibitor. It covalently binds EGFR, HER2 and ErbB4, permanently switching off the signaling that EGFR-mutant cancer cells depend on for survival and growth. This irreversible mechanism differentiates it from first-generation EGFR inhibitors and contributes to its durable clinical benefit.

Indications

The approved indications for Xovoltib are first-line therapy for metastatic non-small cell lung cancer with non-resistant EGFR mutations, and treatment of metastatic squamous non-small cell lung cancer progressing after platinum-based chemotherapy. Confirmation of EGFR mutation status by an approved test is required before use.

Dosage

The recommended dose is 40 mg once daily, taken on an empty stomach — at least one hour before or two hours after food. A 30-tablet pack covers approximately one month at the standard dose. Patients with severe renal impairment should start at 30 mg once daily, and dose modification may be used to manage side effects.

Side Effects

The side effects of Xovoltib mirror those of afatinib generally: diarrhea, acneiform rash, stomatitis, paronychia, dry skin and decreased appetite are common. Less frequent but serious events include interstitial lung disease, hepatotoxicity, keratitis and severe skin reactions. Regular monitoring and early symptom management are important.

Storage

Store Xovoltib tablets at room temperature in the original packaging, away from moisture and heat. Swallow whole with water; do not crush or chew.

Why Choose the GLT?

GLT provides access to the genuine Taiwan-marketed Xovoltib from Boehringer Ingelheim through a dependable, Hong Kong-licensed channel. We verify stock and batch details and provide the documentation needed for confident procurement. For patients and institutions who prefer the originator product in the Taiwan packaging and 30-tablet format, Xovoltib through GLT offers authenticity and reliable supply.

How to Order Xovoltib (Afatinib)

To order, contact our team on WhatsApp at +86 15234153837 or by email at [email protected]. Let us know the quantity and destination, and we will confirm availability and delivery terms.

FAQ

Is Xovoltib the same as Gilotrif? Yes, Xovoltib is afatinib from Boehringer Ingelheim, sold under the Xovoltib brand in the Taiwan market. The active ingredient and quality are identical to Gilotrif.

What strength is available? This listing covers the 40 mg tablets in a 30-tablet pack, the standard once-daily dose.

How should Xovoltib be taken? Take one 40 mg tablet daily on an empty stomach, at least one hour before or two hours after a meal.

Is EGFR testing required? Yes, Xovoltib should only be used in patients with confirmed EGFR mutations detected by an approved test.